BEAM
Price
$25.99
Change
-$1.80 (-6.48%)
Updated
Nov 5, 04:20 PM (EDT)
Capitalization
2.87B
117 days until earnings call
Intraday BUY SELL Signals
LENZ
Price
$3.06
Change
-$0.40 (-11.56%)
Updated
Nov 5, 04:23 PM (EDT)
Capitalization
108.71M
139 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs LENZ

BEAM vs LENZ Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BEAM vs. LENZ commentary
Nov 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and LENZ is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BEAM with price predictions
Nov 04, 2026

BEAM in upward trend: 10-day moving average moved above 50-day moving average on November 03, 2026

The 10-day moving average for BEAM crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on BEAM as a result. In 67 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

BEAM moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +7.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 198 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The 10-day RSI Indicator for BEAM moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 56 cases where BEAM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

BEAM broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.689) is normal, around the industry mean (2.904). P/E Ratio (-40.275) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for LENZ with price predictions
Nov 04, 2026

LENZ's RSI Oscillator ascending out of oversold territory

The RSI Indicator for LENZ moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 25 of the 29 cases the stock moved higher. This puts the odds of a move higher at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 65 cases where LENZ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on LENZ as a result. In 74 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for LENZ just turned positive on October 09, 2026. Looking at past instances where LENZ's MACD turned positive, the stock continued to rise in 45 of 55 cases over the following month. The odds of a continued upward trend are 82%.

Following a +10.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where LENZ advanced for three days, in 234 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

LENZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LENZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for LENZ entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.496) is normal, around the industry mean (2.904). P/E Ratio (-0.838) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (5.903) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. LENZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LENZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
BEAM: Fundamental Ratings
BEAM
OUTLOOK RATING
1..100
10
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
92
PRICE GROWTH RATING
1..100
52
P/E GROWTH RATING
1..100
54
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMLENZ
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 11 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
72%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
COMPARISON
Comparison
Nov 05, 2026
Stock price -- (BEAM: $27.79 vs. LENZ: $3.46)
Brand notoriety: BEAM and LENZ are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 69% vs. LENZ: 101%
Market capitalization -- BEAM: $2.87B vs. LENZ: $108.71M
BEAM [@Biotechnology] is valued at $2.87B. LENZ’s [@Biotechnology] market capitalization is $108.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $139.16B. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green while LENZ’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • LENZ’s FA Score: 1 green, 4 red.
According to our system of comparison, LENZ is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while LENZ’s TA Score has 6 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 4 bearish.
  • LENZ’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, LENZ is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а -3.44% price change this week, while LENZ (@Biotechnology) price change was +7.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.28%. For the same industry, the average monthly price growth was -13.89%, and the average quarterly price growth was -20.84%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 02, 2027.

LENZ is expected to report earnings on Mar 24, 2027.

Industries' Descriptions

@Biotechnology (-8.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DVSP29.410.80
+2.79%
WEBs SPY Defined Volatility ETF (DVSP)
CHIQ16.360.43
+2.70%
Global X MSCI China Consumer Discretionary ETF (CHIQ)
QQQE117.381.43
+1.23%
Direxion NASDAQ-100 Equal Weighted Index ETF (QQQE)
HAP73.860.70
+0.96%
VanEck Natural Resources ETF (HAP)
AAAD48.03N/A
N/A
PGIM AAA CLO Aggregate Duration ETF (AAAD)